Clinical trials: STEMI - ST Elevation Myocardial Infarction
Large Reperfused ST-Elevation Myocardial Infarction
CXCR4 Antagonism for Cell Mobilisation and Healing in Acute Myocardial Infarction (CATCH-AMI)
The purpose of this study is to investigate the effects of POL6326 (CXCR4 antagonist) as a stem cell mobilizing agent, on cardiac function and infarct size and on safety and tolerability, in patients with reperfused ST-Elevation…
- Trial name
- CATCH-AMI (NCT01905475)
- Testing
- POL6326
- Where
- 17 sites in Austria, Germany and 3 more
- Volunteers
- 120 people
- Sponsor
- Polyphor Ltd.
ST Elevation Myocardial Infarction
Study of Efficacy and Safety of GNR-060 vs Metalyse in Patients With ST Elevation Myocardial Infarction
GNR-060(JSC "GENERIUM", Russia) is a proposed biosimilar to the referent product Metalyse. This study is to compare the clinical efficacy and safety of GNR-060 vs Metalyse as a thrombolitic agent in patients with with ST…
- Trial name
- NCT05601999
- Testing
- GNR-060, Metalyse
- Where
- 11 sites in Russia
- Volunteers
- 244 people
- Sponsor
- AO GENERIUM
Acute Coronary Syndromes
A Comparison of Prasugrel at PCI or Time of Diagnosis of Non-ST Elevation Myocardial Infarction
The purpose of this trial is to investigate the potential benefits/risks regarding pretreatment with prasugrel in non-ST-elevation myocardial infarction (NSTEMI) participants with elevated troponin scheduled for coronary…
- Trial name
- ACCOAST (NCT01015287)
- Testing
- Prasugrel
- Where
- 153 sites in Austria, Belgium and 17 more
- Volunteers
- 4,033 people
- Sponsor
- Eli Lilly and Company
Acute Coronary Syndrome
Effect of Otamixaban Versus Unfractionated Heparin + Eptifibatide in Patients With Unstable Angina/Non ST Elevation Myocardial Infarction Undergoing Early Invasive Strategy
Primary Objective: To demonstrate the superior efficacy (composite of all-cause death + Myocardial Infarction (MI)) of Otamixaban to Unfractionated Heparin (UFH) + Eptifibatide Secondary Objectives: To demonstrate the superior…
- Trial name
- TAO (NCT01076764)
- Testing
- Otamixaban, UFH, Eptifibatide
- Where
- 607 sites in United States, Argentina and 53 more
- Volunteers
- 13,220 people
- Sponsor
- Sanofi
STEMI - ST Elevation Myocardial Infarction
ST-segment Elevation Not Associated With Acute Cardiac Necrosis (LESTONNAC)
Patients with chest pain and persistent ST segment elevation (STE) may not have acute coronary occlusions or serum troponin curves suggestive of acute necrosis.
- Trial name
- LESTONNAC (NCT05689970)
- Testing
- AI platform to detect ST elevation in ECG
- Where
- 7 sites in Spain
- Volunteers
- 420 people
- Sponsor
- Idoven 1903 S.L.
Cardiogenic Shock
CorVad Myocardial Infarction Complicated with Cardiogenic Shock Trial
Cardiogenic shock a serious complication of a heart attack (myocardial infarction). Despite evaluation of several new treatments during the last decade, the mortality in patients with cardiogenic shock still exceeds 50%.
- Trial name
- Corvad AMICS (NCT06886113)
- Testing
- Conventional circulatory support, CorVad
- Where
- China
- Volunteers
- 269 people, healthy volunteers welcome
- Sponsor
- Shenzhen Core Medical Technology CO.,LTD.
STEMI - ST Elevation Myocardial Infarction, Anterior MI
Observational Registry to Evaluate Real World Usage of PiCSO Impulse System in STEMI Patients as Part of Post-marketing Surveillance
A prospective, multicenter, single-arm, open label registry of commercially treated patients with PiCSO Impulse System.
- Trial name
- PiCSO-AMI-IV (NCT04566289)
- Testing
- PiCSO
- Where
- Germany
- Sponsor
- Miracor Medical SA
ST Elevation Myocardial Infarction
Effect of DLBS1033 After Primary PCI in Patients With STE-ACS
This is a prospective, randomized, double-blind, double-dummy, and controlled clinical study over a total of 4-week therapy with DLBS1033 in the management of STE-ACS after a primary PCI.
- Trial name
- NCT02976701
- Testing
- DLBS1033, Standard therapy
- Where
- Indonesia
- Volunteers
- 23 people
- Sponsor
- Dexa Medica Group
STEMI - ST Elevation Myocardial Infarction, Inferior Wall Myocardial Infarction
A Study to Evaluate Safety and Feasibility of PiCSO Therapy in Patients With ST Elevation Inferior Wall Myocardial Infarction.
The objective of this study is to assess safety and feasibility of Pressure-controlled intermittent Coronary Sinus Occlusion (PiCSO) therapy in patients with extensive ST elevation inferior wall myocardial infarction presenting…
- Trial name
- PiCSO-AMI-V (NCT04958421)
- Testing
- PiCSO Impulse System
- Where
- 11 sites in Denmark, France and 3 more
- Volunteers
- 25 people
- Sponsor
- Miracor Medical SA
Unstable Angina, Coronary Atherosclerosis
Serp-1 for the Treatment of Acute Coronary Syndrome
Males and females aged 18-80 years who present with ACS (unstable angina and non ST-elevation MI) defined as one or more episodes of angina lasting at least 5 minutes in the last 24 hours before admission and greater than 0.05 mV…
- Conditions
- Unstable Angina, Coronary Atherosclerosis, Coronary Restenosis
- Trial name
- NCT00243308
- Testing
- Serine proteinase-1 (Serp-1)
- Where
- 8 sites in United States, Canada
- Volunteers
- 72 people
- Sponsor
- Viron Therapeutics Inc
Coronary Artery Disease, Unstable Angina
Restore EF Observational Study
A multi-center, prospective, observational, non-interventional single arm, study of the intermediate-term clinical outcomes collected from electronic health records of high-risk patients which have previously undergone standard…
- Conditions
- Coronary Artery Disease, Unstable Angina, Angina, Stable, NSTEMI - Non-ST Segment Elevation MI
- Trial name
- NCT04648306
- Testing
- Prophylactic Impella support for a non-emergent PCI
- Where
- 21 sites in United States
- Volunteers
- 406 people
- Sponsor
- Abiomed Inc.
STEMI - ST Elevation Myocardial Infarction
Asian Registry of the BioFreedom Stent for STEMI Patients
The BioFreedom BA9 (Stainless Steel) Drug Coated Stent is an approved stent that is already commercially available in Europe and Asia.
- Trial name
- NCT03609346
- Testing
- PCI
- Where
- 5 sites in Hong Kong, Singapore and 3 more
- Volunteers
- 914 people
- Sponsor
- Biosensors Europe SA
Coronary Artery Disease
SELUTION 4 De Novo Small Vessel IDE Trial
Prospective, randomized controlled, single-blind, multicenter, clinical trial to demonstrate the safety and efficacy of the SELUTION SLR 014 PTCA DEB for treatment of de novo lesions in small coronary vessels, defined as…
- Trial name
- NCT05946629
- Testing
- PCI with SELUTION SLR DCB, PCI with FDA approved "-limus" DES
- Where
- 70 sites in United States, Belgium and 1 more
- Volunteers
- 960 people
- Sponsor
- M.A. Med Alliance S.A.
Acute Myocardial Infarction, Heart Failure
Inflammation-mediated Coronary Plaque Vulnerability, Myocardial Viability and Ventricular Remodeling
VIABILITY study aims to investigate the link between systemic inflammation, pancoronary plaque vulnerability (referring to the plaque vulnerability within the entire coronary tree), myocardial viability and ventricular remodeling…
- Trial name
- VIABILITY (NCT03830944)
- Testing
- Blood sampling, transthoracic echocardiography, Late Gadolinium-Enhancement Cardiac Magnetic Resonance
- Where
- Romania
- Volunteers
- 150 people
- Sponsor
- Cardio Med Medical Center
Myocardial Infarction
Safety and Efficacy Study of MGuard Stent After a Heart Attack
The goal of this study is to demonstrate the superiority of the MGuard™ stent over commercially-approved bare-metal (BMS) /drug-eluting stents (DES) in achieving better myocardial reperfusion in primary angioplasty for the…
- Trial name
- MASTER (NCT01368471)
- Testing
- MGuard, Control BMS or DES
- Where
- 7 sites in Poland, South Africa
- Volunteers
- 433 people, healthy volunteers welcome
- Sponsor
- InspireMD
Myocardial Infarction, Reperfusion Injury
Prevention of Reperfusion Injury Outcomes Through Effective Cardioprotection Targeting Myocardial Infarction
This study is open to adults with ST elevation myocardial infarction (heart attack) undergoing primary percutaneous coronary intervention (PCI).
- Conditions
- Myocardial Infarction, Reperfusion Injury, AMI, STEMI (ST Elevation MI)
- Trial name
- PROTECT-MI (NCT07362446)
- Testing
- Xolatryp
- Where
- 8 sites in Australia
- Volunteers
- 300 people
- Sponsor
- Nyrada Pty Ltd
Coronary Artery Disease, Stable Angina
Validation of the MedHub AutocathFFR Software Device for Non-Invasive Fractional Flow Reserve (FFR)
This observational study evaluated how well the AutocathFFR software measures fractional flow reserve (FFR) from coronary angiogram images.
- Conditions
- Coronary Artery Disease, Stable Angina, Unstable Angina, Non-ST-Elevation Myocardial Infarction
- Trial name
- NCT07763769
- Testing
- MedHub AutocathFFR
- Where
- 4 sites in United States
- Volunteers
- 277 people
- Sponsor
- Medhub Ltd.
Acute Myocardial Infarction, Acute Myocardial Ischemia
Study of Dutogliptin in Combination With Filgrastim in Post-Myocardial Infarction
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Study of Dutogliptin in Combination with Filgrastim in Early Recovery Post-Myocardial Infarction
- Conditions
- Acute Myocardial Infarction, Acute Myocardial Ischemia, STEMI - ST Elevation Myocardial Infarction
- Trial name
- NCT03486080
- Testing
- Dutogliptin Tartrate, Filgrastim Injectable Product
- Where
- 12 sites in Austria, Belgium and 3 more
- Volunteers
- 49 people
- Sponsor
- Recardio, Inc.
ST Elevation Myocardial Infarction
MGuard™ Prime Embolic Protection Stent in Patients With Acute ST Elevation Myocardial Infarction
Prospective, non-randomized, single arm, multicenter observational study. The objective is to evaluate the safety and efficacy of the MGuard™ Prime stent in the treatment of de novo stenotic lesions in coronary arteries in…
- Trial name
- e-MASTER (NCT02292823)
- Testing
- MGuard™ Prime Embolic Protection Stent System
- Where
- Netherlands
- Volunteers
- 63 people
- Sponsor
- InspireMD
ST Segment Elevation Myocardial Infarction (STEMI), Allogeneic Mesenchymal Bone Marrow Cells
A Study of Allogeneic Mesenchymal Bone Marrow Cells in Subjects With ST Segment Elevation Myocardial Infarction (STEMI)
The purpose of this study is to assess the safety and tolerability of human allogeneic mesenchymal bone marrow cells (aMBMC) administered intravenously to subjects with ST Segment Elevation Myocardial Infarction (STEMI).
- Trial name
- NCT01770613
- Testing
- Stem cells
- Where
- 2 sites in United States
- Sponsor
- Stemedica Cell Technologies, Inc.